Why the study?
Does trial eligibility status affect 30-day and 4-year all-cause mortality in STS-defined low-risk patients undergoing TAVR?
Does trial eligibility status affect 30-day and 4-year all-cause mortality in STS-defined low-risk patients undergoing TAVR?
Answers are grounded in this paper and cite their sources.
In an editorial commentary on the Japanese LAPLACE-TAVI registry, STS-defined low-risk TAVR patients who failed to meet pivotal trial eligibility criteria had substantially higher 30-day and 4-year mortality than trial-eligible patients despite nearly identical STS scores, highlighting the need for individualized heart team assessment beyond surgical risk calculators.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Dai et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: